Intercept Pharma (ICPT) Tops Q2 EPS by $1.00, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports Second Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update
August 10, 2020 7:00 AM EDTWorldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarterÂ
Intercept issues 2020 Ocaliva Net Sales Guidance of $300 to $320 million
Intercept lowers 2020 non-GAAP Adjusted Operating Expense Guidance by $100 million to $460 million to $500 million
Preparations Underway for Type A Meeting with FDA on NASH Fibrosis Program
Conference call scheduled for 8:30 a.m. ET today
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused... More
